The study of Natural Killer (NK) cells in the development of diseases such as pulmonary arterial hypertension: this research could lead to the creation of new immune-based treatments that could reverse changes made in a person’s lungs.
![[Mark Ormiston]](/research/sites/vp2www/files/uploaded_images/researchers/Ormiston-Mark-700x700.jpg)
Former
Tier 2
The role of immune cells in pulmonary arterial hypertension
When people think of the immune system, they usually focus on its ability to fight off infection and combat diseases such as cancer. Mark Ormiston worked to show that immune cells can serve other important functions, including the regulation of blood vessel integrity, growth, and repair.
Dr. Ormiston’s research focused on pulmonary arterial hypertension (PAH), a deadly disease of the blood vessels in the lung that preferentially affects women in their 30s to 50s. Although commonly viewed as a vascular disease, PAH is often linked to autoimmunity and viral infections like HIV.
Dr. Ormiston investigated how impairment of a specific immune cell type, known as the Natural Killer (NK) cell, may be critical to disease development and could offer a new avenue for treatment. While traditionally known for their ability to eliminate viruses and cancer, NK cells have also been shown to regulate changes in uterine blood flow during pregnancy.
By basing his work in these established roles for NK cells in pregnancy and cancer, Dr. Ormiston investigated how similar processes can influence the structure of the lung vasculature in health and disease. The purpose of this research was to develop new immune-based treatments for PAH and other related vascular disorders. To this end, Dr. Ormiston worked on techniques to isolate and genetically modify patient stem cells, with the ultimate goal of creating tailored immune cell therapies that can reverse the vascular changes that devastate the lungs of PAH patients.